Abstract 4254
Background
Nivolumab demonstrated superior overall survival (OS) in clinical trials compared to docetaxel in patients previously treated for squamous (Sq) and non-squamous (NSq) aNSCLC. The objective was to describe in French real-world setting the characteristics and outcomes of patients treated with nivolumab for aNSCLC according to histology.
Methods
Based on the National hospitals database (PMSI), we performed a retrospective cohort of all NSCLC patients (ICD code: C34*) initiating nivolumab in 2015-2016 and followed until Dec 2017. Information on patients’ baseline characteristics (demographics, comorbidities, treatment history) was retrieved for Sq and NSq patients, and time to treatment discontinuation (TTD) with nivolumab and OS were estimated with Kaplan-Meier methodology.
Results
The overall cohort included 10,452 patients. Among them, a majority (N = 5805; 56%) presented NSq histology. Compared to Sq patients (N = 4647), NSq patients were younger (61.9 vs. 66.1 years; p < 0.001) and less frequently men (64.3% vs 79.3%; p < 0.001). They had less comorbidities such as hypertension (15.8% vs 23.0%; p < 0.001), diabetes (6.7% vs 11.7%; p < 0.001) and COPD (8.8% vs 18.1%; p < 0.001). Cerebral metastases were more frequent in the NSq population (22.9% vs 10.1%; p < 0.001). Median time from NSCLC diagnosis to nivolumab initiation was longer in NSq patients (14.2 vs 10.5 months; p < 0.001), as well as median time from first systemic treatment to nivolumab initiation (12.0 vs 8.9 months; p < 0.001). Nivolumab TTD was comparable across histologies with a median treatment duration of 2.8 months (p = 0.556). Proportion of NSq and Sq patients treated were 27.8% vs 25.7% (p < 0.001) at 6-month and 14.6% vs 12.1% (p < 0.001) at 1-year, respectively. Median OS was higher in NSq patients (12.6 vs 10.6 months; p = 0.004). NSq and Sq patients OS rates were 51.1% vs 45.7% (p < 0.001) at 1-year and 29.3% vs 24.6% (p < 0.001) at 2-year, respectively.
Conclusions
This analysis of a large nationwide retrospective cohort assessed patients’ characteristics and outcomes associated with nivolumab treatment in clinical practice in France. In both histologies, results suggest similar TTD and OS in real life setting as those observed in phase III trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bristol-Myers Squibb France.
Funding
Bristol-Myers Squibb.
Disclosure
C. Chouaid: Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb. C. Calvet: Full / Part-time employment: Bristol-Myers Squibb. A. Gaudin: Full / Part-time employment: Bristol-Myers Squibb. V. Grumberg: Full / Part-time employment: Bristol-Myers Squibb. R. Jolivel: Honoraria (institution): Bristol-Myers Squibb. B. Jouaneton: Honoraria (institution): Bristol-Myers Squibb. F. Cotté: Full / Part-time employment: Bristol-Myers Squibb. All other authors have declared no conflicts of interest.
Resources from the same session
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract
1117 - Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine.
Presenter: Shigetaka Suekane
Session: Poster Display session 3
Resources:
Abstract
1922 - Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumor tissues
Presenter: Shaorong Yu
Session: Poster Display session 3
Resources:
Abstract
5495 - Patient’s perspective on digital biomarkers in advanced urologic malignancies
Presenter: Severin Rodler
Session: Poster Display session 3
Resources:
Abstract
3166 - A comprehensive Pan-cancer study of FGFR Aberrations in Chinese cancer patients
Presenter: Yang Gao
Session: Poster Display session 3
Resources:
Abstract
3277 - A Systemic Inflammation Response Index (SIRI) correlates with survival and could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer (PC)
Presenter: Vilma Pacheco-Barcia
Session: Poster Display session 3
Resources:
Abstract
2680 - Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced Non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel)
Presenter: Alberto Pavan
Session: Poster Display session 3
Resources:
Abstract
4066 - Breast cancer in young women of Kazakh population depending on germline mutations: results of next-generation sequencing
Presenter: Dilyara Kaidarova
Session: Poster Display session 3
Resources:
Abstract
5514 - Discovery of an ImmunoTranscriptomics signature in blood for early colorectal cancer detection
Presenter: Paolo Angelino
Session: Poster Display session 3
Resources:
Abstract
1595 - Serum Netrin-1 as a Biomarker for Colorectal Cancer Detection
Presenter: Jinzhou Zhu
Session: Poster Display session 3
Resources:
Abstract